4 days Ago By ABMN Staff
Atyr PHARMA ( NASDAQ:ATYR – Get Free Report ) is expected to announce its Q1 2025 earnings results before the market opens on Thursday, May 1st. Analysts expect the company to announce earnings of ($0.19) per share for the quarter.
Atyr PHARMA ( NASDAQ:ATYR – Get Free Report ) last issued its quarterly earnings results on Thursday, March 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.
23) by $0.05. On average, analysts expect Atyr PHARMA to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Atyr PHARMA Trading Down 2.4 % Shares of ATYR opened at $3.27 on Tuesday.
Atyr PHARMA has a 12-month low of $1.42 and a 12-month high of $4.66.
The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.
02. The firm has a market capitalization of $290.57 million, a price-to-earnings ratio of -3.
48 and a beta of 0.95. The stock’s 50-day moving average price is $3.
35 and its 200 day moving average price is $3.38. Wall Street Analysts Forecast Growth Read Our Latest Research Report on Atyr PHARMA Atyr PHARMA Company Profile ( Get Free Report ) aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways.
Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA. Recommended Stories Receive News & Ratings for Atyr PHARMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atyr PHARMA and related companies with MarketBeat.
com's FREE daily email newsletter ..
